<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180921</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI BFR 17</org_study_id>
    <nct_id>NCT00180921</nct_id>
  </id_info>
  <brief_title>Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck</brief_title>
  <official_title>Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      This is a Phase II study of imatinib (Glivec) administered as a daily oral treatment in&#xD;
      patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck&#xD;
      overexpressing KIT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with relapsing and/or metastatic adenoid cystic carcinoma of the salivary gland of&#xD;
      the head and neck are usually poor responders to conventional cytotoxic chemotherapy.&#xD;
&#xD;
      The investigation of proliferation pathways involving tyrosine kinase receptors such as c-kit&#xD;
      receptor (KIT) and PDGF receptor may allow to identify a molecular target for novel&#xD;
      therapeutic approaches in patients with adenoid cystic carcinoma who failed locoregional&#xD;
      treatment.&#xD;
&#xD;
      Several publications in the literature and the pathological study we conducted in Institut&#xD;
      Gustave Roussy show that KIT overexpression is observed in at least 80-90% of the cases of&#xD;
      adenoid cystic carcinoma, supporting the investigation of imatinib in patients with adenoid&#xD;
      cystic carcinoma overexpressing KIT.&#xD;
&#xD;
      Imatinib is an orally administrated, well tolerated compound that could be given on an&#xD;
      outpatient schedule to patients with relapsing/metastatic adenoid cystic carcinoma of the&#xD;
      head and neck.&#xD;
&#xD;
      Because of the infrequent occurrence of salivary gland malignancies, a multicenter trial will&#xD;
      be mandatory and the study will include at least 2 centers represented by Institut Gustave&#xD;
      Roussy, Villejuif; and HÃ´pital Georges-Pompidou, Paris.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess progression-free survival under treatment with imatinib mesylate in patients with relapsing/metastatic adenoid cystic carcinoma of the head and neck overexpressing KIT.</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives are to estimate the objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria), disease control and overall survival.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cancer of the Head and Neck</condition>
  <condition>Carcinoma, Adenoid Cystic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven adenoid cystic carcinoma overexpressing KIT (by&#xD;
             immunohistochemistry) with recurrent disease documented by computed tomography (CT)&#xD;
             scan or magnetic resonance imaging (MRI).&#xD;
&#xD;
          -  Presence of at least one dimensionally measurable target lesion (contrast enhancing&#xD;
             lesion with the largest diameter &gt;= 2 cm, based on CT or MRI scan done within 4 weeks&#xD;
             before the start of treatment).&#xD;
&#xD;
          -  Patients able to swallow an oral compound.&#xD;
&#xD;
          -  World Health Organization (WHO) performance status &lt; 2.&#xD;
&#xD;
          -  Life expectancy of &gt;= 3 months.&#xD;
&#xD;
          -  Aged &gt;= 18 years.&#xD;
&#xD;
          -  Normal hematological (neutrophils &gt;= 1.5 x 10^9 cells/l, platelets &gt;= 100 x 10^9&#xD;
             cells/l), hepatic (bilirubin &lt; 1.5 times the upper limit of the normal range; alkaline&#xD;
             phosphatase and transaminases &lt;= 2.5 x the upper limit of the normal range) and renal&#xD;
             (serum creatinine &lt;= 150 mmol/l) functions.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal cardiac function with history of ischaemic heart disease in the past 6 months&#xD;
             and/or abnormal 12 lead electrocardiogram (ECG).&#xD;
&#xD;
          -  Previous or current malignancies at other sites with the exception of cone biopsied&#xD;
             carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma.&#xD;
&#xD;
          -  Concomitant treatment with warfarin or any other anticoagulants.&#xD;
&#xD;
          -  Unstable systemic diseases or active uncontrolled infections.&#xD;
&#xD;
          -  Patients (male and female) not using effective contraception if of reproductive&#xD;
             potential.&#xD;
&#xD;
          -  Females pregnant or lactating or positive beta human chorionic gonadotropin (bHCG) at&#xD;
             baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine Faivre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Beaujon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandrine Faivre, MD</last_name>
    <phone>33 1 40 87 50 25</phone>
    <email>s.faivre@bjn.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Faivre, MD</last_name>
      <phone>33 1 40 87 50 25</phone>
      <email>s.faivre@bjn.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Robert, MD</last_name>
      <phone>33 1 42 11 42 53</phone>
      <email>crobert@igr.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 24, 2007</last_update_submitted>
  <last_update_submitted_qc>September 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2007</last_update_posted>
  <keyword>Adenoid cystic carcinoma of the head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

